---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-169805"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T00:59:49.332693+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# CalciMedica announces positive Phase 2b CARPO topline data for Auxora in acute pancreatitis

## Summary
- Trial enrolled 216 patients; primary endpoint met with up to 43.6% relative risk reduction in time to solid food tolerance vs placebo in hyper-inflamed subgroup.
- Auxora showed statistically significant dose response: severe organ failure reduced by up to 61.7% in medium dose vs placebo.
- High dose patients had 0% hospital stays >21 days vs 5.7% placebo; combined high/medium dose showed 84.3% relative risk reduction.
- Auxora well-tolerated: only 1 drug-related treatment-emergent serious adverse event across all dose groups; no related deaths in high dose.
- Company plans End-of-Phase 2 meeting with FDA and intends to present additional CT data at a medical meeting later in 2024.

## SEC filing metadata
- accession: 0001193125-24-169805
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312524169805/0001193125-24-169805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312524169805/d124614d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-169805
- JSON: https://secwatch.observer/filing/0001193125-24-169805.json
- Plain text: https://secwatch.observer/filing/0001193125-24-169805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.